Tomoki Inagaki

This paper develops a gene therapy vector targeting KSHV-infected cells using AAV8-TR2-OriP-TK, which, when combined with ganciclovir, effectively eradicates KSHV-associated cancers in xenograft models.

This study investigates how KSHV terminal repeats (TR) function as enhancers by regulating BRD4 recruitment and promoter activation during viral reactivation.

This study shows that KSHV LANA prevents viral genomic DNA degradation by inhibiting the cGAS-STING pathway, maintaining latency.

This study shows that prolonged KSHV-encoded vIL-6 exposure reprograms chromatin to enhance inflammatory cytokine production through BRD4-mediated mechanisms.